Connect with us

Medtech

Eko Launches SENSORA Cardiac Disease Detection Platform

Eko, a digital health company applying artificial intelligence (AI) in the fight against heart and lung disease, announced the launch of the SENSORA Cardiac…

Published

on

This article was originally published by AITHORITY
Eko Launches SENSORA™ Cardiac Disease Detection Platform

Eko, a digital health company applying artificial intelligence (AI) in the fight against heart and lung disease, announced the launch of the SENSORA Cardiac Disease Detection Platform. SENSORA currently features AI that objectively identifies structural murmurs, a sign of valvular heart disease, and Care Pathway Analytics software that provides downstream visibility and metrics of the patient journey through the healthcare system.

SENSORA is a cardiovascular disease detection platform that combines the latest advancements in applied machine learning with one of the most ubiquitous medical devices in the world: the stethoscope. By capturing and analyzing heart sounds and electrical signals with its digital stethoscopes, Eko has pioneered a detection platform designed to expand as the company develops applications for additional cardiac conditions.

Recommended AI News: T-Mobile Magenta Drive for BMW Powers America’s First 5G Connected Cars

“Our vision for SENSORA is to make cardiovascular disease detection simple and accurate in frontline care settings like primary care and urgent care,” said Connor Landgraf, Co-founder & CEO of Eko. “During a routine physical exam, patients can now have access to advanced structural murmur detection and arrhythmia assessment by their primary care physician in seconds, making early intervention possible for millions of patients with silent cardiovascular disease. We are making the world’s most universal medical exam objective and accurate.”

SENSORA FDA-cleared structural murmur detection helps health systems more accurately and consistently identify valvular heart disease (VHD) in patients during a routine visit with their primary care physician. VHD is a life-threatening condition diagnosed in more than 8 million Americans. Left undetected and untreated, it can lead to heart failure, stroke, blood clots, and death. Older adults have a 1 in 10 chance of developing clinically significant VHD. However, more than half (57%) of clinically significant valvular heart disease goes undetected in this population. A primary care physician using SENSORA for structural murmur detection more than doubles their likelihood of detecting significant VHD.

SENSORA Care Pathway Analytics follows patients with identified structural murmurs through the care continuum, providing downstream visibility into patient flows, clinical outcomes and patient economics. Care Pathway Analytics is designed to assist with critical decision-making by identifying care gaps that can be transformed into improved operational efficiencies, including reduced delays in delivery of care, length of stay, and readmission rates, all while improving patient and physician satisfaction.

Recommended AI News: Mavenir Announces Business Communications Portfolio

“The primary care setting is a patient’s first line of defense for identifying and diagnosing heart disease,” said Dr. John Chorba, Assistant Professor in Residence, Division of Cardiology, Zuckerberg San Francisco General Hospital and Department of Medicine, University of California San Francisco. “However, we know from clinical evidence that detection rates are low. The SENSORA platform promises to better serve patients by increasing the accuracy and consistency of structural murmur identification and improving patients’ lives by getting them into treatment earlier.”

In addition to Eko’s current portfolio of five FDA 510(k) cleared digital solutions, the company has two novel machine learning algorithms in development that apply electrocardiogram (ECG) and heart sound data: a low ejection fraction detection algorithm (named “ELEFT”) to detect a weakened heart pump, which is present in half of heart failure patients, and an algorithm to detect and stratify pulmonary hypertension. Eko is committed to impacting patients and clinicians by creating advanced solutions that meet their needs, enable early detection of heart and lung diseases, and save lives.

Recommended AI News: Titaniam Announces Completion of Product Suite to Push Back on the Ransomware Problem

[To share your insights with us, please write to sghosh@martechseries.com]

The post Eko Launches SENSORA Cardiac Disease Detection Platform appeared first on AiThority.


medicine




devices
digital health
artificial intelligence

machine learning

Medtech

ETF Talk: AI is ‘Big Generator’

Second nature comes alive Even if you close your eyes We exist through this strange device — Yes, “Big Generator” Artificial intelligence (AI) has…

Continue Reading
Medtech

Apple gets an appeals court win for its Apple Watch

Apple has at least a couple more weeks before it has to worry about another sales ban.

Continue Reading
Medtech

Federal court blocks ban on Apple Watches after Apple appeal

A federal appeals court has temporarily blocked a sweeping import ban on Apple’s latest smartwatches while the patent dispute winds its way through…

Continue Reading

Trending